Fly News Breaks for February 27, 2020
Feb 27, 2020 | 07:10 EDT
Barclays analyst Carter Gould initiated coverage of Pfizer with an Equal Weight rating and $36 price target. The analyst initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations. While abrocitinib data is a near-term upside risk to Pfizer shares, the stock is unlikely to break out without additional business development or Ibrance data, says Gould.
News For PFE From the Last 2 Days
Mar 1, 2021 | 07:10 EST
Flowserve (FLS) announced it is providing pumps, valves and seals to Pfizer (PFE) to support production of its COVID-19 vaccine. During the engineering runs of vaccine production Pfizer needed support to replace a mechanical mixer seal on its COVID-19 vaccine production line. The Flowserve Kalamazoo, Michigan team expedited the rebuild of this equipment. Additionally, Flowserve through its channel partner, Corrosion Fluid Products, is providing Pfizer with a cryogenic valve application to support their expanded production capabilities of the COVID-19 vaccine. The Flowserve Cookeville, Tennessee facility will supply Pfizer with more than 200 Worcester cryogenic ball valves that can handle the rigorous temperature requirements needed in supporting the mass production of the COVID-19 vaccine. And finally, Flowserve's Chesapeake, Virginia and Itzehoe, Germany pump manufacturing facilities are providing pumps to Pfizer for both their North American and European vaccine production.